Physician profile
Surender Singh
NPI 1063574457
$12,531.58
in general payments reported to CMS, 2019-2025
35 companies · $24.41 in 2025
The $24.41 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,437 · 2020: $2,333 · 2021: $2,765 · 2022: $2,674 · 2023: $1,777 · 2024: $521 · 2025: $24.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,322.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,453.23 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,568.28 | 2021-2024 | Vraylar |
| Allergan, INC. | $1,069.96 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $965.04 | 2019-2024 | Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $786.04 | 2020-2024 | Caplyta |
| Glaxosmithkline, LLC. | $729.21 | 2019-2023 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $673.41 | 2020-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $521.17 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.11 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $461.96 | 2019-2023 | Trintellix |
| Alkermes, INC. | $401.64 | 2021-2024 | Lybalvi, Aristada |
| Merck Sharp & Dohme LLC | $286.94 | 2019-2023 | Verquvo, Belsomra |
| Novo Nordisk INC | $259.83 | 2019-2023 | Wegovy, Saxenda, Rybelsus |
| Pfizer INC. | $258.44 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $229.30 | 2019-2023 | Spravato |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $222.23 | 2020-2023 | |
| Lundbeck LLC | $202.16 | 2021-2023 | Rexulti |
| Ucb, INC. | $134.15 | 2019 | |
| Eisai INC. | $122.14 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $121.15 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $120.57 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $95.79 | 2022-2023 | Quviviq |
| Bausch Health US, LLC | $73.06 | 2022-2023 | Aplenzin |
| Lilly USA, LLC | $36.67 | 2020 | |
| Esperion Therapeutics, INC. | $33.73 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $31.95 | 2023 | Eliquis |
| Hologic Sales and Service, LLC | $28.58 | 2022 | |
| Sage Therapeutics, LLC | $26.12 | 2023 | |
| Madrigal Pharmaceuticals | $24.41 | 2025 | Rezdiffra |
| Biohaven Pharmaceuticals, INC. | $20.90 | 2021 | |
| Exact Sciences Corporation | $20.38 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $18.98 | 2022 | |
| Acerus Pharmaceuticals Corporation | $18.26 | 2022 | |
| Avanir Pharmaceuticals, INC. | $16.09 | 2019 | |
| Organogenesis INC. | $14.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surender Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.